Literature DB >> 21548109

Identification of serum protein markers for breast cancer relapse with SELDI-TOF MS.

Lei Lei1, Xiao-Jia Wang, Zhi-Guo Zheng, Jian Huang, Wen-Ming Cao, Zhan-Hong Chen, Xi-Ying Shao, Ju-Fen Cai, Wei-Wu Ye, Hong-Yang Lu.   

Abstract

Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) was used to screen serum samples to identify protein markers for early breast cancer relapse. We collected 67 serum samples from patients with breast cancer (24 preoperative; 23 postoperative without breast cancer relapse; 20 postoperative with breast cancer relapse). Eight protein peaks varied between the presurgical group and the postsurgical group without breast cancer relapse; 4 protein peaks were differentially expressed between the postsurgical patients without relapse and patients with relapse. The peak at 3964 m/z dropped after surgery and rebounded after relapse (P < 0.01). These results indicate that there are differences in serum protein expression among the three different groups of patients. SELDI-TOF MS could be used to screen blood samples for the early detection of relapse in primary breast cancer patients. Specifically, protein peak at 3964 m/z is a potential biomarker for the detection of early breast cancer relapse.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21548109     DOI: 10.1002/ar.21399

Source DB:  PubMed          Journal:  Anat Rec (Hoboken)        ISSN: 1932-8486            Impact factor:   2.064


  5 in total

1.  Screening and identification of serum proteomic biomarkers for gastric adenocarcinoma.

Authors:  Chibo Liu; Chunqin Pan; Yong Liang
Journal:  Exp Ther Med       Date:  2012-03-14       Impact factor: 2.447

2.  Reduced expression of SETD2 and SNX9 proteins in chemically induced mammary tumorigenesis in Wistar rats: a prognostic histological and proteomic study.

Authors:  Ishfaq Ahmad Ganaie; Samar Husain Naqvi; Swatantra Kumar Jain; Saima Wajid
Journal:  Protoplasma       Date:  2016-10-20       Impact factor: 3.356

3.  A new tumor biomarker, serum protein peak at 3,144 m/z, in patients with node-positive breast cancer.

Authors:  Z Chen; S Xu; D Su; W Liu; H Yang; S Xie; X Meng; L Lei; X Wang
Journal:  Clin Transl Oncol       Date:  2014-12-16       Impact factor: 3.405

4.  Identification of biomarkers for radiation-induced acute intestinal symptoms (RIAISs) in cervical cancer patients by serum protein profiling.

Authors:  Yanlan Chai; Juan Wang; Ying Gao; Tao Wang; Fan Shi; Jin Su; Yunyi Yang; Xi Zhou; Liping Song; Zi Liu
Journal:  J Radiat Res       Date:  2014-09-24       Impact factor: 2.724

Review 5.  Advances in Proteomic Technologies and Its Contribution to the Field of Cancer.

Authors:  Mehdi Mesri
Journal:  Adv Med       Date:  2014-09-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.